Patient outcomes platform will improve clinical development, says ICON

By Flora Southey contact

- Last updated on GMT

GettyImages/solarseven
GettyImages/solarseven
ICON and the International Consortium for Health Outcomes Measurement's (ICHOM) pilot patient outcomes platform – known as ‘Globe’ – aims to improve drug development procedures.

The platform collates and shares patient outcomes to determine ‘Standard Sets’​, designed to help healthcare providers better understand how to measure outcomes of specific treatment interventions.

“The key is that healthcare providers who own their data, the platform, have access to their data and analysis, will be able to give input in protocols and endpoints that are meaningful to patients and can adjust treatment plans to the benefit of their patients,” ​said Icon CEO Steve Cutler. 

Contract research organisation (CRO) ICON, who is responsible for collecting, storing, aggregating and providing the data back to the participants, said the platform will enhance clinical development.

“The measurement and sharing of outcomes will ultimately improve the clinical development process by enabling better protocols that will lead to the development of treatments that will be of most benefit to patients,” ​said Cutler. 

The services firm said it had collected data from 70 healthcare facilities and developed risk-adjustment algorithms based on more than 75,000 procedures.

“Built into the platform are benchmarking capabilities for hip and knee osteoarthritis and cataracts with three additional conditions being developed throughout 2018 for release by the end of the year,” ​Cutler told us.

Global data

According to Cutler, unlike other services on the market, the Globe platform is designed to collate data from providers worldwide.

“The architecture of the platform enables the consumption of data from geographically, culturally, procedurally and administratively diverse healthcare providers,” ​he said.

The pilot platform is hosted within Icon’s primary data centre, located in Europe, and will open to participants in Q1 2018.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers